Second-Line Therapy for ESA-Refractory, Transfusion Dependent Lower-Risk MDS: Luspatercept

Opinion
Video

Dr Sekeres discusses how he approaches second-line therapy selection in ESA-refractory, transfusion-dependent lower-risk MDS (LR-MDS) patients, specifically with luspatercept.

Recent Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.